Following the divestiture of its US Pharmaceutical Development Services business which included the rights to the AAIPharma name, AAIPharma Inc. has changed its name to ZeeCRO Inc.
ZeeCRO Inc. continues to provide early and late stage development services to its customers worldwide. These services include: Integrated early development services (EU), Pharmaceutical analysis (EU), Clinical trial supplies (EU, SA), Phase 1 (EU), Bioanalysis(NA, EU), Global clinical development services and Oncology development consulting.
The new global headquarters for ZeeCRO is located in Cary, North Carolina, USA.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.